119 related articles for article (PubMed ID: 18559971)
1. Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study.
Kozak W; Kozak A; Johnson MH; Elewa HF; Fagan SC
J Pharmacol Exp Ther; 2008 Sep; 326(3):773-82. PubMed ID: 18559971
[TBL] [Abstract][Full Text] [Related]
2. Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection.
Fagan SC; Kozak A; Hill WD; Pollock DM; Xu L; Johnson MH; Ergul A; Hess DC
J Hypertens; 2006 Mar; 24(3):535-9. PubMed ID: 16467657
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection.
Elewa HF; Kozak A; Johnson MH; Ergul A; Fagan SC
J Hypertens; 2007 Apr; 25(4):855-9. PubMed ID: 17351379
[TBL] [Abstract][Full Text] [Related]
4. Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke.
Brdon J; Kaiser S; Hagemann F; Zhao Y; Culman J; Gohlke P
J Hypertens; 2007 Jan; 25(1):187-96. PubMed ID: 17143191
[TBL] [Abstract][Full Text] [Related]
5. Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.
Omura-Matsuoka E; Yagita Y; Sasaki T; Terasaki Y; Oyama N; Sugiyama Y; Okazaki S; Sakoda S; Kitagawa K
Hypertens Res; 2009 Jul; 32(7):548-53. PubMed ID: 19424281
[TBL] [Abstract][Full Text] [Related]
6. Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.
Krikov M; Thone-Reineke C; Müller S; Villringer A; Unger T
J Hypertens; 2008 Mar; 26(3):544-52. PubMed ID: 18300867
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia.
Fu H; Hosomi N; Pelisch N; Nakano D; Liu G; Ueno M; Miki T; Masugata H; Sueda Y; Itano T; Matsumoto M; Nishiyama A; Kohno M
J Hypertens; 2011 Nov; 29(11):2210-9. PubMed ID: 21934531
[TBL] [Abstract][Full Text] [Related]
8. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats.
Engelhorn T; Goerike S; Doerfler A; Okorn C; Forsting M; Heusch G; Schulz R
J Cereb Blood Flow Metab; 2004 Apr; 24(4):467-74. PubMed ID: 15087716
[TBL] [Abstract][Full Text] [Related]
9. Renal responses of the nonclipped kidney of two-kidney/one-clip Goldblatt hypertensive rats to type 1 angiotensin II receptor blockade with candesartan.
Cervenka L; Navar LG
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S197-201. PubMed ID: 9892163
[TBL] [Abstract][Full Text] [Related]
10. Effects of candesartan on angiotensin II-induced renal vasoconstriction in rats and mice.
Ruan X; Purdy KE; Oliverio MI; Coffman TM; Arendshorst WJ
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S202-7. PubMed ID: 9892164
[TBL] [Abstract][Full Text] [Related]
11. Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats.
Takai S; Jin D; Shimosato T; Sakonjo H; Miyazaki M
Hypertens Res; 2011 Feb; 34(2):245-52. PubMed ID: 21107329
[TBL] [Abstract][Full Text] [Related]
12. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats.
Chung S; Park CW; Shin SJ; Lim JH; Chung HW; Youn DY; Kim HW; Kim BS; Lee JH; Kim GH; Chang YS
Nephrol Dial Transplant; 2010 Feb; 25(2):389-99. PubMed ID: 19749146
[TBL] [Abstract][Full Text] [Related]
13. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
[TBL] [Abstract][Full Text] [Related]
14. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
[TBL] [Abstract][Full Text] [Related]
15. Effects of long-term treatment with candesartan on hemodynamics and organ damage in spontaneously hypertensive rats.
Xie HH; Chen YY; Miao CY; Shen FM; Su DF
Cardiovasc Drugs Ther; 2005 Dec; 19(6):391-7. PubMed ID: 16453089
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with ibuprofen and the AT1 receptor antagonist candesartan in young spontaneously hypertensive rats.
Pollock DM; Morsing P
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S116-9. PubMed ID: 9892151
[TBL] [Abstract][Full Text] [Related]
17. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Engelhorn T; Doerfler A; Heusch G; Schulz R
Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
[TBL] [Abstract][Full Text] [Related]
18. Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats.
Kato N; Liang YQ; Ochiai Y; Birukawa N; Serizawa M; Jesmin S
Hypertens Res; 2008 Oct; 31(10):1963-75. PubMed ID: 19015604
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
[TBL] [Abstract][Full Text] [Related]
20. Low-dose candesartan improves renal blood flow and kidney oxygen tension in rats with endotoxin-induced acute kidney dysfunction.
Nitescu N; Grimberg E; Guron G
Shock; 2008 Aug; 30(2):166-72. PubMed ID: 18091574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
